Efficacy and Safety Study of Orvepitant for Chronic Cough in Patients With Idiopathic Pulmonary Fibrosis

Key Inclusion Criteria: * Diagnosis of IPF established according to the 2018 or 2022 joint ATS/ERS/JRS/ALAT Clinical Practice Guideline * FEV1/FVC ratio ≥0.65 at the screening visit * Haemoglobin-corrected diffusion capacity of carbon monoxide (Hb-corrected DLCO) ≥25% within 12 months of the screening visit * Arterial oxygen saturation on room air or oxygen ≥90% at Screening * Life expectancy of at least 12 months * Cough that is attributed to IPF, which has not responded to anti-tussive treatment, and which has been present for at least 8 weeks prior to Screening * Mean daily IPF Coughing Severity Scale score ≥5 (after rounding) during the second week of the baseline assessment period Key Exclusion Criteria: * Recent respiratory tract infection (\<8 weeks prior to Screening) * Recent acute exacerbation of IPF (\<8 weeks prior to Screening) * Current smokers or ex-smokers with \<6 months' abstinence prior to Screening * Emphysema ≥50% on high-resolution computed tomography, or the extent of emphysema is greater than the extent of fibrosis according to the reported results of the most recent scan * Mean early morning cough scale score ≥5 and rest of the day cough scale score \<5 (after rounding) during the second week of the baseline assessment period (assessed at Visit 2) * Cough that is predominantly productive in nature and attributable to lung pathology such as chronic bronchitis or bronchiectasis